$6.720
-0.079 (-1.18%)收盤時
LGVN 資訊
LGVN 事件
Longeveron Inc Trading Halted, News Pending
Longeveron Inc trading halted, news pending
Longeveron Appoints Nirav Jhaveri as CFO
Longeveron (LGVN) announced that the company has appointed Nirav Jhaveri to the company's executive leadership team in the role of CFO, principal financial officer and principal accounting officer. He succeeds Marie Washburn who stepped into the role following the retirement of the prior CFO. Washburn will return to her former role as the company's corporate controller. Before joining Longeveron, Jhaveri served as CFO of Opus Genetics (IRD).
Longeveron Reports Q2 Revenue of $287,000, Down from $316,000 Last Year
Reports Q2 revenue $287,000 vs. $316,000 last year. "Longeveron is approaching a series of potentially transformative milestones across our four stem cell therapy development programs that have the potential to redefine the trajectory of our business," said Stephen H. Willard, Chief Executive Officer of Longeveron. "Our approach to stem cell therapy development has garnered external recognition and validation with positive clinical data having been published in Nature Medicine and Cell Stem Cell and also serving as the foundation for our selection as a Finalist for the XPRIZE Healthspan competition out of over 600 projects submitted worldwide. We are rapidly approaching the September top line data readout of our ELPIS II Phase 2b clinical trial evaluating laromestrocel in HLHS and look forward to sharing those results."
Longeveron Presents Alzheimer's Clinical Trial Data
Longeveron announced the presentation of additional data from its Phase 2a CLEAR-MIND clinical trial of laromestrocel in patients with mild Alzheimer's disease. The findings, presented at the Alzheimer's Association International Conference, indicate that the cellular therapy stabilizes brain inflammation in key gray and white matter regions. The reduction in inflammation, measured as free water, correlated with both increased brain volume and improved cognitive and quality of life scores. Longeveron has received U.S. Food and Drug Administration Regenerative Medicine Advanced Therapy and Fast Track designations for the program. "We believe these results provide important validation of the therapeutic potential of laromestrocel in the treatment of mild Alzheimer's disease," said Joshua Hare, co-founder, chief science officer, and executive chairman at Longeveron. "We look forward to continuing partnering discussions to advance this potentially important new option for addressing Alzheimer's disease."
Longeveron Appoints Marie Washburn as CFO
Longeveron announced that the company has appointed Marie Washburn to the company's executive leadership team in the role of senior VP and CFO, principal financial officer and principal accounting officer, effective July 13. She succeeds Lisa Locklear who, as previously announced, is stepping down to pursue board opportunities and other professional and personal interests. Washburn has served as the company's VP and corporate controller since November 2025.
本頁僅供研究參考，不構成投資建議。模型可能出錯。過往表現不代表未來結果。